Michelle L O'Donoghue1, David A Morrow2, Sotirios Tsimikas3, Sarah Sloan2, Angela F Ren2, Elaine B Hoffman2, Nihar R Desai4, Scott D Solomon5, Michael Domanski6, Kiyohito Arai7, Stephanie E Chiuve8, Christopher P Cannon2, Frank M Sacks9, Marc S Sabatine2. 1. TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: modonoghue@partners.org. 2. TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. 3. Division of Cardiovascular Diseases, University of California San Diego, La Jolla, California. 4. Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine; Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, Connecticut. 5. Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. 6. Mount Sinai School of Medicine, Cardiovascular Division, New York, New York. 7. Division of Cardiovascular Diseases, University of California San Diego, La Jolla, California; Division of Cardiology, Tokyo Women's Medical University, Tokyo, Japan. 8. Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 9. Channing Laboratory and Cardiology Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
OBJECTIVES: The purpose of this study was to assess the prognostic utility of lipoprotein(a) [Lp(a)] in individuals with coronary artery disease (CAD). BACKGROUND: Data regarding an association between Lp(a) and cardiovascular (CV) risk in secondary prevention populations are sparse. METHODS: Plasma Lp(a) was measured in 6,708 subjects with CAD from 3 studies; data were then combined with 8 previously published studies for a total of 18,978 subjects. RESULTS: Across the 3 studies, increasing levels of Lp(a) were not associated with the risk of CV events when modeled as a continuous variable (odds ratio [OR]: 1.03 per log-transformed SD, 95% confidence interval [CI]: 0.96 to 1.11) or by quintile (Q5:Q1 OR: 1.05, 95% CI: 0.83 to 1.34). When data were combined with previously published studies of Lp(a) in secondary prevention, subjects with Lp(a) levels in the highest quantile were at increased risk of CV events (OR: 1.40, 95% CI: 1.15 to 1.71), but with significant between-study heterogeneity (p = 0.001). When stratified on the basis of low-density lipoprotein (LDL) cholesterol, the association between Lp(a) and CV events was significant in studies in which average LDL cholesterol was ≥130 mg/dl (OR: 1.46, 95% CI: 1.23 to 1.73, p < 0.001), whereas this relationship did not achieve statistical significance for studies with an average LDL cholesterol <130 mg/dl (OR: 1.20, 95% CI: 0.90 to 1.60, p = 0.21). CONCLUSIONS: Lp(a) is significantly associated with the risk of CV events in patients with established CAD; however, there exists marked heterogeneity across trials. In particular, the prognostic value of Lp(a) in patients with low cholesterol levels remains unclear.
OBJECTIVES: The purpose of this study was to assess the prognostic utility of lipoprotein(a) [Lp(a)] in individuals with coronary artery disease (CAD). BACKGROUND: Data regarding an association between Lp(a) and cardiovascular (CV) risk in secondary prevention populations are sparse. METHODS: Plasma Lp(a) was measured in 6,708 subjects with CAD from 3 studies; data were then combined with 8 previously published studies for a total of 18,978 subjects. RESULTS: Across the 3 studies, increasing levels of Lp(a) were not associated with the risk of CV events when modeled as a continuous variable (odds ratio [OR]: 1.03 per log-transformed SD, 95% confidence interval [CI]: 0.96 to 1.11) or by quintile (Q5:Q1 OR: 1.05, 95% CI: 0.83 to 1.34). When data were combined with previously published studies of Lp(a) in secondary prevention, subjects with Lp(a) levels in the highest quantile were at increased risk of CV events (OR: 1.40, 95% CI: 1.15 to 1.71), but with significant between-study heterogeneity (p = 0.001). When stratified on the basis of low-density lipoprotein (LDL) cholesterol, the association between Lp(a) and CV events was significant in studies in which average LDL cholesterol was ≥130 mg/dl (OR: 1.46, 95% CI: 1.23 to 1.73, p < 0.001), whereas this relationship did not achieve statistical significance for studies with an average LDL cholesterol <130 mg/dl (OR: 1.20, 95% CI: 0.90 to 1.60, p = 0.21). CONCLUSIONS:Lp(a) is significantly associated with the risk of CV events in patients with established CAD; however, there exists marked heterogeneity across trials. In particular, the prognostic value of Lp(a) in patients with low cholesterol levels remains unclear.
Authors: M G Shlipak; J A Simon; E Vittinghoff; F Lin; E Barrett-Connor; R H Knopp; R I Levy; S B Hulley Journal: JAMA Date: 2000-04-12 Impact factor: 56.272
Authors: Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone Journal: Circulation Date: 2004-07-13 Impact factor: 29.690
Authors: Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene Journal: N Engl J Med Date: 2004-03-08 Impact factor: 91.245
Authors: Gérald Luc; Jean-Marie Bard; Dominique Arveiler; Jean Ferrieres; Alun Evans; Philippe Amouyel; Jean-Charles Fruchart; Pierre Ducimetiere Journal: Atherosclerosis Date: 2002-08 Impact factor: 5.162
Authors: Nader Rifai; Jing Ma; Frank M Sacks; Paul M Ridker; Wendy Jade L Hernandez; Meir J Stampfer; Santica M Marcovina Journal: Clin Chem Date: 2004-05-20 Impact factor: 8.327
Authors: Michael N Zairis; John A Ambrose; Stavros J Manousakis; Alexander S Stefanidis; Olga A Papadaki; Helen I Bilianou; Mary C DeVoe; Constantine N Fakiolas; Evangelos G Pissimissis; Christopher D Olympios; Stefanos G Foussas Journal: J Am Coll Cardiol Date: 2002-10-16 Impact factor: 24.094
Authors: John J Albers; April Slee; Kevin D O'Brien; Jennifer G Robinson; Moti L Kashyap; Peter O Kwiterovich; Ping Xu; Santica M Marcovina Journal: J Am Coll Cardiol Date: 2013-08-21 Impact factor: 24.094
Authors: V W Armstrong; P Cremer; E Eberle; A Manke; F Schulze; H Wieland; H Kreuzer; D Seidel Journal: Atherosclerosis Date: 1986-12 Impact factor: 5.162
Authors: Yanglu Zhao; Joseph A Delaney; Ruben G W Quek; Julius M Gardin; Calvin H Hirsch; Shravanthi R Gandra; Nathan D Wong Journal: Clin Cardiol Date: 2016-05-13 Impact factor: 2.882
Authors: Sotirios Tsimikas; Sergio Fazio; Keith C Ferdinand; Henry N Ginsberg; Marlys L Koschinsky; Santica M Marcovina; Patrick M Moriarty; Daniel J Rader; Alan T Remaley; Gissette Reyes-Soffer; Raul D Santos; George Thanassoulis; Joseph L Witztum; Simhan Danthi; Michelle Olive; Lijuan Liu Journal: J Am Coll Cardiol Date: 2018-01-16 Impact factor: 24.094
Authors: Gregory G Schwartz; Christie M Ballantyne; Philip J Barter; David Kallend; Lawrence A Leiter; Eran Leitersdorf; John J V McMurray; Stephen J Nicholls; Anders G Olsson; Prediman K Shah; Jean-Claude Tardif; John Kittelson Journal: JAMA Cardiol Date: 2018-02-01 Impact factor: 14.676